|
|
|
|
Vol. 304, Issue 1, 411-424, January 2003
in Two Murine Models of Colitis
Isis Pharmaceuticals, Carlsbad, California (K.J.M., D.R.W., M.B.,
Su.M., A.S., D.G., B.B.); MCP Hahnemann University, Philadelphia,
Pennsylvania (Sr.M., A.F.); and University of Alberta, Edmonton,
Alberta, Canada (K.M.)
Tumor necrosis factor-
(TNF-
) is a key cytokine involved
in the pathogenesis of inflammatory bowel disease. We have developed a
second-generation antisense oligonucleotide (ISIS 25302)
specific for murine TNF-
and have evaluated this oligonucleotide in
two models of gut inflammation of distinct etiology. ISIS 25302 decreased TNF-
mRNA in a dose- and sequence-dependent manner in
vitro in the mouse macrophage cell line P388D1. It also reduced TNF-
mRNA in vivo, in whole adipose tissue and in macrophages isolated from the adipose tissue of db/db mice, a
strain with constitutively high expression of TNF-
. ISIS 25302 significantly reduced disease activity index scores in mice with both
an acute and a chronic form of dextran sodium sulfate (DSS)-induced
colitis. It also significantly improved histopathological scores in
interleukin (IL)-10-deficient mice. This was accompanied by reductions
in both the basal and lipopolysaccharide-stimulated secretion of TNF-
and interferon-
in colonic organ cultures from IL-10
/
mice. In this model, efficacy was obtained with both a prophylactic treatment regimen or a therapeutic dosing protocol begun after colitis
was already present. In both the DSS and IL-10
/
models, scrambled
and mismatch control oligonucleotides were largely without effect,
suggesting that ISIS 25302 was exerting its effects through a
sequence-dependent antisense mechanism.
This article has been cited by other articles:
![]() |
M. Onizawa, T. Nagaishi, T. Kanai, K.-i. Nagano, S. Oshima, Y. Nemoto, A. Yoshioka, T. Totsuka, R. Okamoto, T. Nakamura, et al. Signaling pathway via TNF-{alpha}/NF-{kappa}B in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis Am J Physiol Gastrointest Liver Physiol, April 1, 2009; 296(4): G850 - G859. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Buanne, E. Di Carlo, L. Caputi, L. Brandolini, M. Mosca, F. Cattani, L. Pellegrini, L. Biordi, G. Coletti, C. Sorrentino, et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice J. Leukoc. Biol., November 1, 2007; 82(5): 1239 - 1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kohno, R. Suzuki, Y. Yasui, S. Miyamoto, K. Wakabayashi, and T. Tanaka Ursodeoxycholic Acid versus Sulfasalazine in Colitis-Related Colon Carcinogenesis in Mice Clin. Cancer Res., April 15, 2007; 13(8): 2519 - 2525. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G De Vry, S. Prasad, L. Komuves, C. Lorenzana, C. Parham, T. Le, S. Adda, J. Hoffman, N. Kahoud, R. Garlapati, et al. Non-viral delivery of nuclear factor-{kappa}B decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis Gut, April 1, 2007; 56(4): 524 - 533. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fujii, C. Zhu, Y. Wen, H. Marusawa, B. Bailly-Maitre, S.-i. Matsuzawa, H. Zhang, Y. Kim, C. F. Bennett, W. Jiang, et al. HBXIP, Cellular Target of Hepatitis B Virus Oncoprotein, Is a Regulator of Centrosome Dynamics and Cytokinesis. Cancer Res., September 15, 2006; 66(18): 9099 - 9107. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Law, E. M. Labut, R. D. Adams, and J. L. Merchant An isoform of ZBP-89 predisposes the colon to colitis Nucleic Acids Res., March 3, 2006; 34(5): 1342 - 1350. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Gao, A H Wagner, S Fankhaenel, T Stojanovic, S Schweyer, S Panzner, and M Hecker CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis Gut, January 1, 2005; 54(1): 70 - 77. [Abstract] [Full Text] [PDF] |
||||